Novo Nordisk A/S (NVO)
45.76
+0.43
(+0.95%)
USD |
NYSE |
Sep 01, 10:09
Novo Nordisk Cash from Operations (TTM) : 20.59B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.59B |
| March 31, 2026 | 15.42B |
| December 31, 2025 | 18.08B |
| September 30, 2025 | 18.71B |
| June 30, 2025 | 17.84B |
| March 31, 2025 | 21.96B |
| December 31, 2024 | 17.72B |
| September 30, 2024 | 17.23B |
| June 30, 2024 | 16.72B |
| March 31, 2024 | 13.59B |
| December 31, 2023 | 15.80B |
| September 30, 2023 | 15.25B |
| June 30, 2023 | 12.64B |
| March 31, 2023 | 11.89B |
| December 31, 2022 | 11.14B |
| September 30, 2022 | 9.706B |
| June 30, 2022 | 9.806B |
| March 31, 2022 | 10.47B |
| December 31, 2021 | 8.742B |
| September 30, 2021 | 9.501B |
| June 30, 2021 | 8.805B |
| March 31, 2021 | 8.293B |
| December 31, 2020 | 7.947B |
| September 30, 2020 | 8.535B |
| June 30, 2020 | 8.301B |
| Date | Value |
|---|---|
| March 31, 2020 | 6.987B |
| December 31, 2019 | 7.016B |
| September 30, 2019 | 7.381B |
| June 30, 2019 | 6.682B |
| March 31, 2019 | 6.950B |
| December 31, 2018 | 7.065B |
| September 30, 2018 | 6.973B |
| June 30, 2018 | 7.164B |
| March 31, 2018 | 6.132B |
| December 31, 2017 | 6.246B |
| September 30, 2017 | 6.857B |
| June 30, 2017 | 7.126B |
| March 31, 2017 | 7.810B |
| December 31, 2016 | 7.182B |
| September 30, 2016 | 6.999B |
| June 30, 2016 | 6.582B |
| March 31, 2016 | 6.181B |
| December 31, 2015 | 5.692B |
| September 30, 2015 | 5.454B |
| June 30, 2015 | 5.804B |
| March 31, 2015 | 5.512B |
| December 31, 2014 | 5.639B |
| September 30, 2014 | 5.423B |
| June 30, 2014 | 4.331B |
| March 31, 2014 | 4.114B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| AstraZeneca PLC | 14.54B |
| Johnson & Johnson | 27.61B |
| Eli Lilly & Co. | 28.08B |
| Merck & Co., Inc. | 19.97B |
| Novartis AG | 18.41B |